GAITHERSBURG, Md., Sept. 10 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373. Conference details are as follows: Citi 15th Annual BioPharma Virtual Conference Date: [...]
BONN, GERMANY, Sept. 7 (Korea Bizwire) – With first emergency use authorizations for COVID-19 vaccines expected to be effective in the last quarter of 2020, logistics providers are challenged to rapidly establish medical supply chains to deliver more than ten billion doses worldwide. DHL, working with McKinsey & Company as analytics partner, has published a white [...]
SEJONG, Sept. 4 (Korea Bizwire) — South Korea’s finance ministry said Friday it has set aside 170.7 billion won (US$143 million) to help local companies develop homegrown vaccines and treatment drugs next year to fight the coronavirus pandemic. Of the budget, 31.9 billion won will be spent to discover candidate materials for a potential vaccine [...]
GAITHERSBURG, Md., Sept. 2 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication in The New England Journal of Medicine of Phase 1 data from its Phase 1/2 clinical trial of NVX‑CoV2373, its COVID‑19 vaccine candidate adjuvanted with Matrix‑M™, in healthy adults 18-59 [...]
GAITHERSBURG, Md., Aug. 31 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine. “We are pleased to work with [...]
GAITHERSBURG, Md., Aug. 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The [...]
SEOUL, Aug. 21 (Korea Bizwire) — South Korea is moving to secure a sufficient supply of coronavirus vaccines through close international cooperation and local development, the government said Friday. The move comes as countries around the world have been racing to find drugs that can combat the pandemic that has killed more than 796,000 around [...]
GAITHERSBURG, Md., Aug. 17 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will [...]
GAITHERSBURG, Md., Aug. 14 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has signed a Heads of Terms (Term Sheet) with the Government of the United Kingdom (UK) for the purchase of 60 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine, and [...]
GAITHERSBURG, Md. and SEOUL, South Korea, Aug. 13 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and SK bioscience, a vaccine business subsidiary of SK Group, today announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for [...]